A Alabama overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
38.9% of Alabama adults have obesity, per the CDC's 2024 BRFSS prevalence data 4 — a rate that ties Arkansas for 4th-5th highest among the 50 states, trailing only West Virginia (41.4%), Mississippi (40.4%), and Louisiana (39.2%), against a 33.1% national rate the same year 4.
Across 5,157,699 residents 5, the question that decides what treatment actually costs here is not the prevalence figure. It is a state drug list effective July 1, 2026, and what that document marks non-covered.
No. Alabama Medicaid does not cover GLP-1 medications for obesity or weight loss. The agency's own Preferred Drug List Reference Tool, effective July 1, 2026, lists Zepbound as "non-covered for weight reduction without OSA" — covered only for obstructive sleep apnea with obesity, not for obesity alone — and lists Wegovy as "non-covered for weight reduction," available only through prior authorization for its cardiovascular-risk-reduction and MASH indications 1.
The rest of the GLP-1 class — Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza, and Byetta — sits in the PDL's Diabetic Agents section as preferred with clinical criteria 12, meaning it is covered for managing type 2 diabetes, not for weight loss.
Alabama has also not adopted the ACA's Medicaid expansion. The state's own published eligibility categories — children, pregnant women, parent and caretaker relatives, the elderly and disabled, nursing-home care, breast and cervical cancer, and family planning — leave no general category for low-income working-age adults 3. For most adults in Alabama, that means there is no Medicaid route to a GLP-1 prescription for weight loss at all, regardless of income.
With Medicaid closed to the weight-loss indication, most Alabamians looking at a GLP-1 are looking at a cash price.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
Census ACS estimates put Alabama's uninsured rate at 8.2% and median household income at $66,659 6 — the backdrop against which a fixed, published self-pay price matters more than in states with broader coverage.
Physicians prescribing to Alabama residents over telehealth are licensed and regulated by the Alabama Board of Medical Examiners.
TODO (verify before publish): confirm the current Alabama Administrative Code telehealth-practice rules — required exam type, any prior in-person-visit requirement, and controlled-substance limits — directly from the board before this section cites a specific rule number. Not independently verified in this research pass; this is a flagged data gap, not a guess.
Astra treats patients in Alabama and in all 50 states. Intake, prescription, and refills happen online, with medication shipped from a state-licensed US compounding pharmacy.
Astra treats patients in Alabama through state-licensed physicians.
Local clinic pricing, specialist access, and Medicaid detail for four Alabama metros:
No. Alabama Medicaid's own Preferred Drug List (effective July 1, 2026) explicitly marks Zepbound and Wegovy "non-covered for weight reduction." The rest of the GLP-1 class is covered only for type 2 diabetes management, not obesity — Alabama residents on Medicaid have no pathway to a covered GLP-1 for weight loss today.
No — and we won't pretend otherwise. Astra's price is the same in every state: $68/month for semaglutide and $118/month for tirzepatide on a 12-month plan ($816 and $1,416 billed annually), including Alabama. There's no city or state discount; the number you see here is the number you'll pay.
No. A population-level statistic like 38.9% adult obesity describes Alabama, not any one person's eligibility. Whether a GLP-1 is appropriate for you depends on your own BMI, health history, and a licensed clinician's evaluation — the consult decides, not the state's obesity rate.
Yes. Because Alabama Medicaid doesn't cover GLP-1s for weight loss and hasn't expanded eligibility to most working-age adults, many Alabama residents are already paying out of pocket by default. Astra's self-pay price is fixed and published up front — $68/month or $118/month depending on medication — with no insurance requirement.
Yes. Astra is licensed to treat patients in all 50 states, including Alabama. Care is delivered by telehealth: an online consult with a licensed clinician determines whether a GLP-1 is appropriate, and prescriptions are filled through Astra's pharmacy network.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.